Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
North America to Become Cryptomining Central Now That China Miners Have Gone Dark
Bitfarms Ltd. (NASDAQ: BITF), a green cryptocurrency miner with five industrial-scale facilities located in Que´bec, is the newest NASDAQ-listed crypto play, joining the exchange on June 21, 2021. Since starting its Bitcoin Inventory Pilot Program in early January 2021, Bitfarms has been adding almost all newly mined Bitcoins to its balance sheet to the tune of 1,114 mined Bitcoin through June 9. Since its founding in 2017, Bitfarms has mined over 11,300 Bitcoin with 100% renewable hydropower.
As it happens, the news from China shocked the market, but it didn't change the trajectory for digital currencies in the grand scheme of things. No one in the market seems rattled about it and, fact is, it has afforded a rare opportunity for expeditious growth for companies big and small as outsiders matriculate to the U.S. and Canada.
https://www.prnewswire.com/news-releases/north-america-to-become-cryptomining-central-now-that-china-miners-have-gone-dark-301332097.html
8 Wall Street analysts have issued ratings and price targets for Paysafe in the last 12 months. Their average twelve-month price target is $17.00, predicting that the stock has a possible upside of 47.57%. The high price target for PSFE is $19.00 and the low price target for PSFE is $15.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
https://www.marketbeat.com/stocks/NASDAQ/PSFE/price-target/
Affimed: Remaining Bullish Despite Study Discontinuation
https://seekingalpha.com/article/4438388-affimed-remaining-bullish-despite-study-discontinuation
Bitcoin miner revenue jumps by 50% in 4 days since record difficulty drop
https://cointelegraph.com/news/bitcoin-miner-revenue-jumps-by-50-in-4-days-since-record-difficulty-drop
Bitfarms: Decline In Bitcoin Hash Rate Appears To Fully Offset Price Decline
https://thedeepdive.ca/bitfarms-decline-in-bitcoin-hash-rate-appears-to-fully-offset-price-decline/
Bitcoin mining is now easier and more profitable as algorithm adjusts after China crackdown
https://www.cnbc.com/2021/07/03/bitcoin-mining-difficulty-drops-after-hashrate-collapse-in-china-.html
Always, it`s just publicity for Bitfarms Ltd..
Fried Bitcoin Hash: China's Takeout Will Be Delivered Globally
https://seekingalpha.com/article/4437518-fried-bitcoin-hash-chinas-takeout-will-be-delivered-globally
Good post and points.
Added at $2.75 in 2 accts. and will continue to add as i`m new to bitfarming stocks, but have been trading Bitcoin since inception & Bitcoin Cash since 2017.
Now instead of trading Bitcoin and the paperwork involved at tax time, i`m loading $BITF and will watch Bitfarms take the lead from other miners. I`ll now just add to my Bitcoin positions without trading physical Bitcoin while Bitfarms does the heavy lifting for me as a miner.
I see other Bitfarm stocks on the move but after listening to all their conference calls, Bitfarms management is the one that sticks out above the others and could easily be acquired down the road or buyout other green miners.
New listings take time to flush out. This one currently is being apprised as the bad boy on the block when it should be welcomed as healthy competition as a low cost producer.
Time will tell.
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2021 Results - Earnings Call Transcript
https://seekingalpha.com/article/4437496-affimed-n-v-afmd-ceo-adi-hoess-on-q1-2021-results-earnings-call-transcript
China’s Bitcoin Mining Crackdown Is a Boon for Miners Elsewhere
“We are now mining more bitcoin on a daily basis than we were before, without doing anything, without adding any machines,” confirms Geoff Morphy, president of Bitfarms, which mines primarily in Quebec, but has plans to expand. Its stock was listed on the Nasdaq on June 21.
https://finance.yahoo.com/news/china-bitcoin-mining-crackdown-boon-125322852.html
For those that have not had a chance to listen to this yet.
2021 | Annual General and Special Meeting virtually
Crypto Stocks: Hash Rate Collapse Is A Windfall For Bitcoin Miners - We're Bullish
https://seekingalpha.com/article/4437014-crypto-stocks-hash-rate-collapse-windfall-for-bitcoin-miners-bullish
Key Bitcoin price indicator flashes its ‘fifth buy signal in BTC history’
https://cointelegraph.com/news/key-bitcoin-price-indicator-flashes-its-fifth-buy-signal-in-btc-history
Key Bitcoin price indicator flashes its ‘fifth buy signal in BTC history’
https://cointelegraph.com/news/key-bitcoin-price-indicator-flashes-its-fifth-buy-signal-in-btc-history
Nothing more than paid click bait. Better if they just bought some shares, then kicked back and watched the shares grow. It would net them more than pennies on the dollar for a very poorly written article.
I just hope others go to the link and give people the real story. If nothing else its free advertising I guess.
Cathie Wood’s ARK Invest files to create a bitcoin ETF
https://www.cnbc.com/2021/06/28/cathie-woods-ark-invest-files-to-create-a-bitcoin-etf.html
Cathie Wood’s ARK Invest files to create a bitcoin ETF
https://www.cnbc.com/2021/06/28/cathie-woods-ark-invest-files-to-create-a-bitcoin-etf.html
Time is on our side once listed. There are not enough players and we are not in a crowed field.
Paysafe: One Payments Firm To Pass On For Now
Another sad sack article. I like different opinions, but some take it too far. This Stone Fox Capital needs some common sense rebuttals.
https://seekingalpha.com/article/4436891-paysafe-one-payments-firm-to-pass-on-for-now
A Crypto-Revolution In Argentina
https://www.forbes.com/sites/afontevecchia/2021/06/28/a-crypto-revolution-in-argentina/?sh=3d89aef02529
Bitfarms: A 5x Upside Pure-Play Green BTC Mining Company And Its Valuation Framework
https://seekingalpha.com/article/4436806-bitfarms-a-5x-upside-pure-play-green-btc-mining-company-and-its-valuation-framework
Should I Buy Paysafe Limited (PSFE)?
https://www.insidermonkey.com/blog/should-i-buy-paysafe-limited-psfe-954677/
Seems one is never to late to the game in Bitcoin unless you do not own any. "Opportunity does not waste time with those who are unprepared."
Bitcoin NEEDS To Do This To Become Bullish
https://video-ideas.tradingview.com/1/1802075-Juis4zlKFWsf577h.mp4
Excellent direct and to the point video, appreciate the share.
I sold my position seeing gold is not really being used as a hedge for inflation as it has been in the past. Instead i`ve moveed those assets to MLP`s in the energy sector and Bitcoin. I do not believe Powell when he says inflation is transitory even though he is just playing to the party line.
Since I sold out of my gold positions i`m up on paper and see energy & Bitcoin as the perfect inflation hedge. GLTU if your still hold gold. I believe it will be rocky for the miners for years going forward.
Adding some here but $CRIS technically is sitting right on the 1 year 200 day SMA and if that breaks through, then a move lower is possible. Stock needs to hold or close above $7.57.
$CRIS- B RILEY- Is confident that the asset is moving forward at a therapeutically relevant dose. I will add a very well done last report-Looking at Swimmer’s plot, we note that two AML patients remain on therapy for >200 days, both of which were treated at 300 mg BID RP2D
B RILEY-Views news positively and remains bullish on CA-4948’s potential in both AML and HR MDS. Curis was appropriately responding to desire of leukemia physicians to push the limits of dosing to try and maximize potential anti-tumor effects in extremely aggressive indications.
I`m thinking ibrutinib combo data in lymphoma coming at ASH also believe as well supposedly NF-kb better addressed via the combo of both agents.
Thank you.
Seems this message board has its usual resident unintelligent troll! You have to wonder what kind of life this person has. It`s really pathetic ie. "miserably inadequate; of very low standard as the true meaning states."
Curis' Plunge Is A Buying Opportunity
https://seekingalpha.com/article/4434596-curis-plunge-is-a-buying-opportunity
Let`s see you poke holes in what is a serious understanding of what the company is really doing if you even understand the science. OBTW- I`m a new investor that's really done some due diligence.
The company announced virtual symposium "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond," taking place on June 18th. Discussion will center on VISTA's role in several disease areas and current development programs (led by two key leaders in the space). It is encouraging to see the company lay groundwork ahead of initial clinical data (expected by year end).
As for Jefferies presentation some highlights:
-NHL study BTK combination has readout year end, as does VISTA program.
-IRAK4 works differently for lymphoma versus leukemia. This year everyone has been focusing on AML/MDS study (where IRAK4L is driver of disease). Testing so far shows all comers in AML & MDS seem to benefit on this drug (getting tumor reduction across the spectrum). As combo therapy, they think all comers should be taking the drug (oral, disease modifying, no myelosuppression that's seen with azacitidine or venetoclax).
-Identified opportunity for accelerated approval with FDA for monotherapy. Easy way to identify these patients, preselect, in advance is with one of two spliceosome mutations. There is spectrum of IRAK4L expression, everyone has some. The more IRAK4L you have, the more likely it is to be problematic and a driver of disease. If in general more IRAK4L is potentially problematic, there are two ways to identify them (IRAK4L assay or 1 of those 2 spliceosome mutations). Roughly 20% of patient population within AML and MDS has a spliceosome mutation. That said, they are getting 8 of 9 patients in study showing blast count reductions (clearly don't have to have one of these two mutations to benefit). There are a lot of patients where simply knocking down IRAK4L expression levels will benefit.
-Original theory has panned out in the lab, reinforced by literature in the industry and now they have clinical data (more and more confidence in this consistent line of thinking). In particular, one of things they have not seen in clinic yet but are designing a cohort to examine is FLT3 mutation. All 3 patients with spliceosome mutation have responded (if in post HMA setting, there are NO approved therapies because NOTHING works). 3 of 3 where NOTHING works is pretty compelling. FLT3 drug was designed to hit FLT3, literature outside of Curis seems to point to these two pathways having a connection (IRAK4 is an escape mechanism for FLT3). Stands to reason that should see extra bump in efficacy there as well, so designed a cohort to test that hypothesis and could have a high class headache (two paths to accelerated approval, horse race to see which one wins).
-Talking to KOLs in community, this is the first time a new target has been identified in AML and MDS for years and it just happens to be the single largest target ever identified.
-EHA data confirms hypothesis and learnings from ASH. 8 of 9 patients now showing blast count reductions (can still say this is an all comers drug). 2nd, have been able to identify mutations most likely to respond that allow for monotherapy accelerated path to market. 3rd, seeming hematological recovery in ALL patients that have responses and some of them all the way back up to normal range (any improvement means fewer transfusions and clear clinical benefit). That they are seing that kind of recovery in these patients is exciting at this stage.
-Data cutoff for abstract was February 8th, and patients that came on after is for 500 mg which is above safety cutoff range. What we should expect is richer data set on patients in the original EHA abstract (baseline characteristics, IRAK4 status, genomics, etc). Enriched dataset gives more confidence on where the drug could be able to go.
-For VISTA, event on 18th Curis is sponsor but more an academic forum, led by two major experts in the space, and there will be lot of people and few other companies to push VISTA forward. Share some of what they are learning and make VISTA a bigger topic.
-Assuming they declare phase 2 dose in leukemia study soon, will move into expansion fast (FLT3, combo patients, spliceosome). Lymphoma study is ongoing as well, combination with ibrutinib. BTK downregulate NFkb and so does IRAK4- preclinical data set is really strong, shows combination of two pathways better than either one alone. Last 2 years they showed monotherapy activity, ibrutinib combo study is ongoing and commercial discussion with physicians is that there are a lot of choices for BTK, but here is only one IRAK4.
Updated EHA data:
-300 mg BID chosen as go forward dose into phase 2 studies (no DLTs at this dose, 98% target inhibition, all 4 patients achieved blast reductions including CRi and negative MRD)
-FLT3 patient achieved objective response, after two cycles FLT3 mutation was ¨completely eradicated¨
-Preclinical synergy supports combination trials with venetoclax and azacitidine
-Genomic analysis from multiple patients is quite supportive (DNA sequencing demonstrates disease modficiation with reduction of cancer associated variant allele frequency, RNA sequencing shows disease modification with reduction in long/short ratio of IRAK4 post treatment)
-Individual case studies (AML patient with spliceosome mutation SF3B1, AML patient with FLG3 mutation, AML patient 4 prior lines of chemo obtaining full recovery of hematologic parameters, nice durability on trial)
-On the con side, they did see two more cases of Grade 3 rhabdomyolysis at the 400mg dose (resolved after dose interruption, no renal dysfunction)
As for the KOL call, here are some takeaways:
-2 paths to potential accelerated approval in monotherapy, genomics analysis confirms disease modification in both patient subgroups. Broad registrational pathway in combination with other agents. Blast count reductions in 10 of 12 patients, 5 objective responses including all 3 spliceosome patients and complete erradication of FLT3 mutation in patient unresponsive to leading FDA approved FLT3 inhibitor.
-Patients that had a response was associated with recovery of platelets and neutrophils. They are seeing blast reduction and decrease in molecular tumor burden.
-Bottom line, IRAK4 is fundamental driver of disease across AML and MDS. Case study from patient 3 was quite convincing, complex mutation status, had some blast reduction (not all the way to normal range), been maintained on drug with stable disease, steady improvement in hematologic parameters (strong support of heme improvement and blast reduction to go into combinations, even if there's not a specific marker that indicates regulatory pathway).
-More thoughts on 300mg BID as recommended phase 2 dose. Excellent exposure curve, tight PK (98% target inhibition). Go to 400mg did not add significant additional effect on target versus 300 mg. 300mg is same dose as lymphoma trials as well as low risk MDS study. Had patients on treatment 7 to 8 months without cumulative toxicity, on lymphoma for up to 2 years this dose. Efficacy is maintained over significant periods of time. 4 of 4 patients with blast count reduction, including CRi with negative MRD. Rapidly moving forward with this dose.
-Preclinical data highly supportive of combination with azacitidine and venetoclax. Azacitidine 4948 combo completely eliminates tumor growth THP-1 cell line (has increased levels of IRAK4L), superior to venetoclax azacitidine combo in that model. Triplet combo suggests strong synergy as well. OCI-AML2 cell line 4948 venetoclax combination ¨completely stops¨ growth in tumor cells and triplet causes ¨profound cell killing¨. Both azacitidine and venetoclax are highly myelosuppressive, is a dose limiting issue and we now have a drug showing clear synergy that does not have additive myelotoxicity.
-Q&A: Across both populations majority of patients have excess IRAK4L for variety of reasons, so would suggest this is a broad drug. 3 spliceosome patients had striking responses, but it's early days. Challenge is this is an extremely poor patient population in terms of survival, they don't live long (survival extremely short, prognosis very poor). Durability seen in patients shown so far is quite striking in that context. Survival after first line therapy in patient with HMA failure is 4 to 6 months, patients with AML particularly those treated with HMA + BCL2 inhibitor is few weeks. There is no standard of care here and very unfortunate situation per KOL, swimmer plot quite encouraging in that light.
-Clinical development plan is long term, has activity in majority of AML and MDS patients so will be an ideal combination partner. Broad strategy is adding earlier line across broad spectrum of AML and MDS. Opportunity for rapid registrational approval in genetically defined populations. Studies going on in parallel.
-Investigator initiated study led by leading expert in low risk MDS studying 4948 as monotherapy (wide open for therapies in this population).
-Very safe go forward dose, getting responses and best responses as monotherapy in exactly the setting they hoped to.
-Combo cohorts are kicking off right now, will do doublets first to make sure data consistent before heading into triplet.
-Big caveat here continues to be the small N, number of patients for which we've seen data so far. Devil's advocate is AML patients responding less than MDS, drug has narrower therapeutic index given upper limit is probably 400mg BID.
-Looking to add as many patients as they can now that they've chosen 300mg dose, love to be able to give an update on these patients at ASH. Keep in mind they've dosed at this level along a couple years without any DLTs. Saw some safety signals above this dose, easily identified, easily resolved and there were not many of them (rhabdo in 13% of patients treated at 400mg). Inhibition percentages at 97, 98 98 among 300mg 400mg 500mg levels. Patient case study 3 clearly seeing benefit on drug despite not having spliceosome or FLT3 mutation, example of ideal candidate for someone going on combo therapy in earlier line.
I encourage everyone to do their own due diligence and make a decision on the current facts and what a stock could return as an investment.
AAV & Lentiviral Gene Therapies with Sio's Dr. Pavan Cheruvu Podcast
20_12_BPO_BusBiotech_Social_ep46
Fresh on the heels of a significant data readout on its AXO-AAV-GM1 candidate at the recent ASGCT meeting, Sio Gene Therapies CEO Pavan Cheruvu, M.D. joins the Business of Biotech podcast. We discuss Dr. Cheruvu's formative years and inspiration, his company's origins, its progress developing AAV and lentiviral gene therapies to treat GM1 gangliosidosis, Tay-Sachs / Sandhoff disease, and Parkinson's disease, and the challenges the company has overcome in a hybrid manufacturing environment that will ultimately transfer entirely in-house.
https://www.cellandgene.com/doc/aav-lentiviral-gene-therapies-with-sio-s-dr-pavan-cheruvu-0001?vm_tId=
Why I Pick MLPX Over AMLP, ENFR And MLPA
https://seekingalpha.com/article/4433580-why-global-x-mlp-energy-infrastructure-etf-mlpx-over-amlp-enfr-mlpa
Showing very oversold with a tilt to the upside near term just needs to work off some excess sellers like taken out stop losses.
$AFMD June presentation https://www.affimed.com/wp-content/uploads/Affimed-N.V._CP_June-2021.pdf
Aptevo Therapeutics: Positive Trial Results, Tang Capital Offer, Proxy Fight
http://clarkstreetvalue.blogspot.com/2021/02/aptevo-therapeutics-positive-trial.html?m=1
A little off topic but all here have added to my gains and I wanted to return the favor(-;
PSFE-Added again-
$APVO do your D&D-Aptevo Therapeutics to $50 from $64 and keeps a Buy rating on the shares. Aschoff views the potential Tang Capital takeout at $50/share as highly likely, and therefore a more relevant investment catalyst, the analyst tells investors in a research note. This one will blow your socks off. Only has 4.4 million shares outstanding plus a $50.00 take out offer. Currently trading @ $25.85 making this almost a certain 100% gainer. Have a good weekend all......
Aptevo Therapeutics price target lowered to $50 from $64 at Roth Capital
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Aptevo Therapeutics to $50 from $64 and keeps a Buy rating on the shares. Aschoff views the potential Tang Capital takeout at $50/share as highly likely, and therefore a more relevant investment catalyst, the analyst tells investors in a research note.
Sio Gene Therapies: Gene Therapies For Neurodegeneration
May 28, 2021 12:30 AM ETSio Gene Therapies, Inc. (SIOX)
https://seekingalpha.com/article/4431842-sio-gene-therapies-gene-therapies-for-neurodegeneration